Tislelizumab-induced anaphylactic shock: a case report
Abstract Immune-checkpoint inhibitors (ICIs) have transformed cancer therapy, but immune-related adverse events (irAEs) remain a major concern. Tislelizumab—a humanised anti-PD-1 monoclonal antibody—has a favourable safety profile; thus, severe hypersensitivity reactions are rarely reported. A 61-ye...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03171-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|